News
Equity Financing
MinervaX announces that the company has raised DKK 16 million (EUR 2.2 million) for the development of its Group B Streptococcal Vaccine. The financing was a combination of an...
Innovation Foundation Grant
MinervaX announces that the company has been awarded a grant worth DKK 4.5 million (EUR 0.6 million) from the Danish Innovation Foundation, under the Innobooster Programme, for...
Initiation of Phase I Part B
MinervaX announces that it today has dosed the first subject in it Phase I Part B Dose-confirmation trial on its Group B Streptococcal vaccine GBS-NN, due to enrol 240 healthy...
Participation in Bill & Melinda Gates Foundation Grant
MinervaX announces that the company is a participant in a BMGF grant worth USD 0.5 million. Awarded to Professor Sharbir Madhi, South Africa for studies on correlates of...
Initiation of Phase I clinical trial
MinervaX initiates phase I clinical trial with innovative Group B Streptococcal (GBS) vaccine to prevent life-threatening infections in newborns. Novel, single component vaccine...
Equity and Loan Financing
Group B Streptococcal vaccine for the prevention of life-threatening infections in newborns secures funding to reach clinical proof of concept. MinervaX, a privately held Danish...
FP7 Grant
Group B Streptococcal vaccine for the prevention of life-threatening infections in newborns secures funding to reach clinical proof of concept. NeoStrep, a consortium consisting...
Eurostar Grant
MinervaX announces the award of a Eurostars Grant in collaboration with Bioneer (Denmark), The Danish Technical University (Denmark) and Telormedix (Switzerland) for the...
Technology Foundation Grant
MinervaX Announces the award of a grant from The Danish National Advanced Technology Foundation together with The State Serum Institute and University of Copenhagen for the...
